Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs RIZATRIPTAN BENZOATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Acute treatment of migraine with or without aura in adults.,Acute treatment of migraine with or without aura in pediatric patients 6 to 17 years of age.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
2-3 hours in adults; clinically, no significant accumulation with multiple dosing.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Primarily metabolized by monoamine oxidase A (MAO-A) via oxidative deamination; minor metabolism by aldehyde oxidase. The major metabolite is the inactive N-desmethyl rizatriptan.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Primarily hepatic metabolism via monoamine oxidase-A, with ~14% excreted unchanged in urine; total recovery of radioactivity in urine is ~82% (30% unchanged drug, 52% metabolites) and ~9% in feces over 24 hours.
99% bound; primary binding protein: albumin.
14%
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
140 L (approximately 2 L/kg in adults), indicating extensive tissue distribution.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Oral: ~45% (due to first-pass metabolism); intranasal: ~42% (compared to subcutaneous sumatriptan); orally disintegrating tablet: ~45%.
No dosage adjustment required for renal impairment.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No dosage adjustment required for hepatic impairment.
Not recommended in patients with severe hepatic impairment (Child-Pugh class C) due to absence of studies. For mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment; use caution.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Children 6-17 years: 5-10 mg orally at onset; may repeat after 2 hours; maximum 30 mg per 24 hours. Weight <40 kg: start 5 mg. Weight ≥40 kg: may use 10 mg.
No specific dosage adjustment required; use same dosing as for younger adults.
Elderly patients may have increased risk of adverse effects. Start at 5 mg; use caution with comorbidities and concomitant medications. No specific dose adjustment required; monitor cardiovascular status.
No FDA boxed warning.
None
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Risk of myocardial ischemia and/or infarction, coronary artery vasospasm, cerebrovascular events, and increased blood pressure. Serotonin syndrome (especially when co-administered with other serotonergic drugs). Use only after clear diagnosis of migraine; not for use in hemiplegic or basilar migraine. Caution in patients with risk factors for coronary artery disease. Avoid use within 24 hours of other 5-HT1 agonists or ergotamine derivatives. Monitor for signs/symptoms of serotonin syndrome.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
History of ischemic heart disease (angina, myocardial infarction, silent ischemia), coronary artery vasospasm (Prinzmetal's angina), or other significant cardiovascular disease. Uncontrolled hypertension. Hemiplegic or basilar migraine. Use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication. Concurrent use or within 2 weeks of monoamine oxidase inhibitor (MAOI) therapy. Known hypersensitivity to rizatriptan or any component. Severe hepatic impairment (Child-Pugh class C).
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
No significant food interactions. However, high-fat meals may delay absorption. Avoid alcohol as it may worsen headaches or increase side effects.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats or rabbits but was associated with embryo-fetal toxicity at maternotoxic doses. Use only if potential benefit justifies potential risk to the fetus. First trimester: no specific data, but theoretical risk of vasoconstriction. Second and third trimesters: may cause uterine contractions or reduced uterine blood flow.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Rizatriptan is excreted in human milk at very low levels; the milk-to-plasma ratio is approximately 0.07. The estimated infant dose is about 3% of the maternal weight-adjusted dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for rizatriptan and potential adverse effects on the breastfed infant.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume, altered metabolism) may reduce exposure. Use lowest effective dose for shortest duration. If migraine severity warrants, standard dosing (5-10 mg oral, may repeat after 2 hours, max 30 mg/24h) may be used.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for acute migraine. Onset of action is rapid (30 min). Maximum daily dose is 30 mg (oral tablets) or 30 mg (ODT). Do not use within 24 hours of other triptans or ergotamines. Contraindicated in patients with ischemic heart disease, uncontrolled hypertension, or basilar/hemiplegic migraine. Avoid in patients with moderate/severe hepatic impairment. ODT dissolves quickly and can be taken without water, useful for patients with nausea.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Take at the first sign of migraine headache; it will not prevent attacks.,Do not exceed 30 mg in any 24-hour period (separate doses by at least 2 hours).,If first dose does not work, do not take a second dose for the same attack without consulting your doctor.,Seek emergency care if you experience chest pain, shortness of breath, or sudden severe headache.,Inform your doctor if you have heart disease, high blood pressure, or are taking MAOIs (within 2 weeks) or other migraine medications.
No interactions on record
"Co-administration of rizatriptan, a selective 5-HT1B/1D receptor agonist, with sertraline, a selective serotonin reuptake inhibitor (SSRI), increases the risk of serotonin syndrome due to additive serotonergic effects. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients should be monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, especially during initiation or dose escalation."
"Paroxetine, a selective serotonin reuptake inhibitor (SSRI), inhibits the metabolism of rizatriptan, a triptan used for migraine, via CYP1A2 and possibly other pathways, leading to increased rizatriptan plasma concentrations. This elevates the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular abnormalities, autonomic instability, and altered mental status. Clinically, patients may experience symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia, requiring prompt recognition and management."
"The combination of rizatriptan, a serotonin 5-HT1B/1D receptor agonist, and ziprasidone, an atypical antipsychotic with serotonergic activity (5-HT2A antagonist and weak serotonin reuptake inhibition), may increase the risk of serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This additive serotonergic effect occurs through overlapping mechanisms, including enhanced 5-HT1A and 5-HT2A receptor activation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs RIZATRIPTAN BENZOATE, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. RIZATRIPTAN BENZOATE is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds with high affinity to 5-HT1B and 5-HT1D receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby reducing migraine-associated neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and RIZATRIPTAN BENZOATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of RIZATRIPTAN BENZOATE is: 5-10 mg orally at onset of migraine; may repeat after 2 hours if headache recurs; maximum 30 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and RIZATRIPTAN BENZOATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. RIZATRIPTAN BENZOATE is classified as Category D/X. Rizatriptan is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, rizatriptan was not teratogenic in rats o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.